Marshall Wace, LLP Bellus Health Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$7.14 - $8.53 $439,338 - $524,867
-61,532 Reduced 3.89%
1,520,633 $10.9 Million
Q4 2022

Feb 14, 2023
SELL
$8.22 - $10.76 $631,435 - $826,550
-76,817 Reduced 4.63%
1,582,165 $13 Million
Q3 2022

Nov 14, 2022
BUY
$8.95 - $12.0 $8.03 Million - $10.8 Million
896,878 Added 117.68%
1,658,982 $17.5 Million
Q2 2022

Aug 15, 2022
BUY
$6.46 - $10.02 $4.92 Million - $7.64 Million
762,104 New
762,104 $7.04 Million

Others Institutions Holding BLU

# of Institutions
1
Shares Held
128K
Call Options Held
0
Put Options Held
0
View Full List

About BELLUS Health Inc.

BLU Quotes by TradingView
  • Ticker BLU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 125,793,000
  • Description
  • BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...
More about BLU
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email